BAY 41-8543,鸟苷酸环化酶（sGC）刺激物|BAY 41-8543|cas:256498-66-5|西域试剂

BAY 41-8543,鸟苷酸环化酶（sGC）刺激物,BAY 41-8543,99.95%

产品编号：Bellancom-W062836| CAS NO：256498-66-5| 分子式：C₂₁H₂₁FN₈O| 分子量：420.44

本网站销售的所有产品仅用于工业应用或者科学研究等非医疗目的,不可用于人类或动物的临床诊断或者治疗,非药用,非食用，

货号	价格	库存与货期
Bellancom-W062836	￥1400.00	杭州北京（现货）
Bellancom-W062836	￥2200.00	杭州北京（现货）
Bellancom-W062836	￥4400.00	杭州北京（现货）
Bellancom-W062836	￥7400.00	杭州北京（现货）

增值税发票√顺丰快递√订货电话：18601927057

BAY 41-8543,鸟苷酸环化酶（sGC）刺激物

产品介绍

BAY 41-8543 是口服有效的，不依赖一氧化氮 (NO) 的可溶性鸟苷酸环化酶 (sGC) 的刺激物。BAY 41-8543 在大鼠的肺和全身血管床中具有血管舒张活性。BAY 41-8543 具有抗血小板作用，并有用于心血管疾病研究的潜力。

生物活性

BAY 41-8543 is an orally active, nitric oxide (NO)-independent stimulator of soluble guanylyl cyclase (sGC). BAY 41-8543 has vasodilator activity in the pulmonary and systemic vascular beds in the rat. BAY 41-8543 has antiplatelet effects and has the potential for cardiovascular diseases research.

体外研究

体内研究

BAY 41-8543 (10-100 μg/kg; IV) produces small decreases in pulmonary arterial pressure, larger dose-dependent decreases in systemic arterial pressure, and increases in cardiac output.
BAY 41-8543 (0.003, 0.01, 0.03, 0.1, and 0.3 mg/kg; iv) produces a dose-dependent and long-lasting decrease in blood pressure in anaesthetized rats. The blood pressure lowering effect of BAY 41-8543 lasts longer than the observation period of 30 min. BAY 41-8543 (0.1, 0.3 and 1.0 mg kg; oral) has maximal blood pressure lowering effects. The blood pressure lowering effects of the highest doses of BAY41-8543 lasts longer than the observation period of 120 min.
BAY 41-8543 (3 mg/kg; p.o.; twice daily; for 5 weeks) completely prevents the development of the increase in systolic blood pressure in 18-week-old renin transgenic rats (TGR(mRen2)27) on L-NAME treatment. BAY 41-8543 dramatically increases survival.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Adult male Sprague-Dawley rats weighing 325-450 g
Dosage:	10, 30, and 100 μg/kg
Administration:	IV
Result:	Produced small decreases in pulmonary arterial pressure, larger dose-dependent decreases in systemic arterial pressure, and increases in cardiac output.

体内研究

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Adult male Sprague-Dawley rats weighing 325-450 g
Dosage:	10, 30, and 100 μg/kg
Administration:	IV
Result:	Produced small decreases in pulmonary arterial pressure, larger dose-dependent decreases in systemic arterial pressure, and increases in cardiac output.

性状

Solid

溶解性数据

In Vitro:

DMF : 16.67 mg/mL (39.65 mM; Need ultrasonic)

Ethanol : 1 mg/mL (2.38 mM; ultrasonic and warming and heat to 70°C)

DMSO : < 1 mg/mL (ultrasonic;warming;heat to 60°C) (insoluble or slightly soluble)

配制储备液

浓度溶剂体积质量	1 mg	5 mg	10 mg

1 mM	2.3785 mL	11.8923 mL	23.7846 mL
5 mM	0.4757 mL	2.3785 mL	4.7569 mL
10 mM	0.2378 mL	1.1892 mL	2.3785 mL

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式